Aradigm Corp (ARDM.OB)

ARDM.OB

About

Aradigm Corporation is a specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company's lead development candidates are formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150)... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	1.34
Market Cap (Mil.):	$38.76
Shares Outstanding (Mil.):	251.69
Dividend:	--
Yield (%):	--

Financials

	ARDM.OB	Industry	Sector
P/E (TTM):	--	34.45	32.18
EPS (TTM):	-0.04	--	--
ROI:	-155.26	-2.81	18.91
ROE:	--	-3.51	19.87

Latest News about ARDM.OB

Grifols signs deal to license Aradigm's Pulmaquin

MADRID, May 21 - Spanish drugmaker Grifols said on Tuesday it has signed an exclusive contract to license U.S. Aradigm Corporation's Pulmaquin compound and may take a stake in the California-based firm.

21 May 2013

» More ARDM.OB News

Competitors

	Price	Change
Johnson & Johnson (JNJ.N)	$86.57	-0.06
Pfizer Inc. (PFE.N)	$27.70	-0.08
Novartis AG (NOVN.VX)	CHF67.45	+0.15
Bayer AG (BAYGn.DE)	€81.71	-0.66
Bayer AG (BAYE.F)	--	--
GlaxoSmithKline plc (GSK.L)	1,670.00p	+11.50
Gilead Sciences, Inc. (GILD.OQ)	$52.23	+0.57
MAP Pharmaceuticals Inc. (MAPP.OQ)	--	--
Alexza Pharmaceuticals, Inc. (ALXA.OQ)	$4.24	-0.09
Insmed Incorporated (INSM.OQ)	$10.04	+0.32

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Aradigm Corp Provider: S&P Capital IQ Quantitative Report	$69.00 Buy
Aradigm Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Aradigm Corporation (ARDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy
Aradigm Corporation (ARDM) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratios and Financial Averages Provider: Plunkett Research, Ltd.	$99.00 Buy
Aradigm Corporation (ARDM) Profile and Financials, plus Biotechnology Industry Trends Analysis, Operating Ratios and Financial Averages Provider: Plunkett Research, Ltd.	$99.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.